{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:41:00Z","timestamp":1792806060344,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.msard.2026.108010","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:07:15Z","timestamp":1792422435000},"page":"108010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world treatment in pediatric-onset multiple sclerosis: Data from the Swiss pediatric inflammatory brain disease cohort study"],"prefix":"10.1016","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9355-9158","authenticated-orcid":false,"given":"Lisa","family":"Sanak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Hulliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Diem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Flachenecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Bigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2026.108010_bib0001","article-title":"Use of disease-modifying therapies in pediatric relapsing-remitting multiple sclerosis in the United Kingdom","volume":"8","author":"Abdel-Mannan","year":"2021","journal-title":"Neurol: Neuroimmunol. Neuroinflammation"},{"issue":"9_Supplement_2","key":"10.1016\/j.msard.2026.108010_bib0002","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1212\/WNL.0000000000002883","article-title":"Pediatric multiple sclerosis: cognition and mood","volume":"87","author":"Amato","year":"2016","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2026.108010_bib0003","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/jnnp-2019-322138","article-title":"Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study","volume":"91","author":"Arnold","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"20","key":"10.1016\/j.msard.2026.108010_bib0004","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"Association","year":"2013","journal-title":"JAMA"},{"issue":"11_Supplement_1","key":"10.1016\/j.msard.2026.108010_bib0005","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1212\/WNL.0000000000216038","article-title":"Efficacy and safety of Ocrelizumab compared with Fingolimod in pediatric-onset relapsingremitting MS: results of the phase III OPERETTA two study (S40. 005)","volume":"106","author":"Banwell","year":"2026","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2026.108010_bib0006","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1474-4422(07)70196-5","article-title":"Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study","volume":"6","author":"Banwell","year":"2007","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.108010_bib0008","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1212\/01.wnl.0000198257.52512.1a","article-title":"Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis","volume":"66","author":"Banwell","year":"2006","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2026.108010_bib0007","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1212\/01.WNL.0000152896.35341.51","article-title":"The cognitive burden of multiple sclerosis in children","volume":"64","author":"Banwell","year":"2005","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2026.108010_bib0009","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/jamaneurol.2021.1008","article-title":"Risk of persistent disability in patients with pediatric-onset multiple sclerosis","volume":"78","author":"Baroncini","year":"2021","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.108010_bib0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/jamaneurol.2023.5566","article-title":"Highly effective therapies as first-line treatment for pediatric-onset multiple sclerosis","volume":"81","author":"Benallegue","year":"2024","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.108010_bib0011","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.msard.2013.06.004","article-title":"Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years","volume":"3","author":"Benson","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2026.108010_bib0012","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1177\/1352458514527862","article-title":"Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network","volume":"20","author":"Charvet","year":"2014","journal-title":"Mult. Scler. J."},{"issue":"9","key":"10.1016\/j.msard.2026.108010_bib0013","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/brain\/awaa199","article-title":"Improved relapse recovery in paediatric compared to adult multiple sclerosis","volume":"143","author":"Chitnis","year":"2020","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.msard.2026.108010_bib0014","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2026.108010_bib0015","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1352458508101933","article-title":"Demographics of pediatric-onset multiple sclerosis in an MS center population from the northeastern United States","volume":"15","author":"Chitnis","year":"2009","journal-title":"Mult. Scler. J."},{"issue":"5","key":"10.1016\/j.msard.2026.108010_bib0016","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/ana.26052","article-title":"Early predictors of 9-year disability in pediatric Multiple sclerosis","volume":"89","author":"De Meo","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.108010_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101431","article-title":"Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis","volume":"37","author":"Erdal","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"16_supplement","key":"10.1016\/j.msard.2026.108010_bib0019","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1212\/WNL.88.16_supplement.P1.346","article-title":"Final results from the BETAPAEDIC study of interferon beta-1b for treatment-na\u00efve pediatric patients with relapsing-remitting MS (P1. 346)","volume":"88","author":"G\u00e4rtner","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2026.108010_bib0020","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40120-024-00633-6","article-title":"Old and new strategies in the treatment of pediatric multiple sclerosis: a personal view for a new treatment approach","volume":"13","author":"Ghezzi","year":"2024","journal-title":"Neurol. Ther."},{"issue":"3","key":"10.1016\/j.msard.2026.108010_bib0021","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/1352458520930620","article-title":"The introduction of new medications in pediatric multiple sclerosis: open issues and challenges","volume":"27","author":"Ghezzi","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"9_Supplement_2","key":"10.1016\/j.msard.2026.108010_bib0022","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1212\/WNL.0000000000002823","article-title":"Pediatric multiple sclerosis: conventional first-line treatment and general management","volume":"87","author":"Ghezzi","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2026.108010_bib0024","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WCO.0000000000000561","article-title":"Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm","volume":"31","author":"Giovannoni","year":"2018","journal-title":"Curr. Opin. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.108010_bib0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archneurol.2008.505","article-title":"Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis","volume":"66","author":"Gorman","year":"2009","journal-title":"Arch. Neurol."},{"issue":"13","key":"10.1016\/j.msard.2026.108010_bib0026","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1177\/1352458520937644","article-title":"What does first-line therapy mean for paediatric multiple sclerosis in the current era?","volume":"27","author":"Hacohen","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"2","key":"10.1016\/j.msard.2026.108010_bib0027","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/jnnp-2012-303996","article-title":"Long-term outcome of paediatric-onset multiple sclerosis: a population-based study","volume":"84","author":"Harding","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.108010_bib0028","first-page":"301","article-title":"Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen, S2k-Leitlinie","author":"Hemmer","year":"2021","journal-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie"},{"issue":"4","key":"10.1016\/j.msard.2026.108010_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0290908","article-title":"Protocol on establishing a national disease registry\u2013Swiss Pediatric Inflammatory Brain Disease Registry","volume":"19","author":"Hulliger","year":"2024","journal-title":"PLOS ONE"},{"key":"10.1016\/j.msard.2026.108010_bib0030","first-page":"022","article-title":"S1-Leitlinie 022\/014: P\u00e4diatrische Multiple Sklerose","author":"Huppke","year":"2016","journal-title":"AWMF Online"},{"key":"10.1016\/j.msard.2026.108010_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105669","article-title":"Delayed initiation of disease modifying therapy increases relapse frequency and motor disability in pediatric onset multiple sclerosis","volume":"87","author":"Jafarpour","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.108010_bib0033","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/0883073812464816","article-title":"Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network","volume":"28","author":"Julian","year":"2013","journal-title":"J. Child. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2026.108010_bib0034","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458515616701","article-title":"Inclusion of brain volume loss in a revised measure of \u2018no evidence of disease activity\u2019(NEDA-4) in relapsing\u2013remitting multiple sclerosis","volume":"22","author":"Kappos","year":"2016","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.108010_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101956","article-title":"Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: a prospective Danish cohort study","volume":"40","author":"Kopp","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2026.108010_bib0036","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult. Scler. J."},{"issue":"15_supplement","key":"10.1016\/j.msard.2026.108010_bib0037","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1212\/WNL.94.15_supplement.625","article-title":"Real-world effectiveness of initial treatment with newer versus injectable disease-modifying therapies in pediatric multiple sclerosis (625)","volume":"94","author":"Krysko","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2026.108010_bib0038","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25737","article-title":"Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis","volume":"88","author":"Krysko","year":"2020","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.108010_bib0039","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s13311-017-0568-1","article-title":"Bringing the HEET: the argument for high-efficacy early treatment for pediatric-onset multiple sclerosis","volume":"14","author":"McGinley","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.msard.2026.108010_bib0040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/acn3.51244","article-title":"Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients","volume":"8","author":"Menascu","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2026.108010_bib0041","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.108010_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105751","article-title":"Real-world evidence from Germany and the United States: treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis","volume":"88","author":"Papukchieva","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"25","key":"10.1016\/j.msard.2026.108010_bib0043","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa067597","article-title":"Natural history of multiple sclerosis with childhood onset","volume":"356","author":"Renoux","year":"2007","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.msard.2026.108010_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103277","article-title":"Current international trends in the treatment of multiple sclerosis in children\u2014Impact of the COVID-19 pandemic","volume":"56","author":"Sandesj\u00f6","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2026.108010_bib0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1600-0404.1992.tb05086.x","article-title":"Early onset MS under the age of 16: clinical and paraclinical features","volume":"86","author":"Sindern","year":"1992","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.msard.2026.108010_bib0046","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10072-022-06431-y","volume":"44","author":"Skarlis","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2026.108010_bib0047","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejpn.2022.06.013","article-title":"Newer disease modifying treatments in pediatric onset multiple sclerosis: experience from a single center","volume":"39","author":"Solmaz","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2026.108010_bib0048","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208114","article-title":"Comparative effectiveness of natalizumab, fingolimod, and injectable therapies in pediatric-onset multiple sclerosis: a registry-based study","volume":"102","author":"Spelman","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.108010_bib0049","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00415-008-6022-x","article-title":"Paediatric multiple sclerosis: the experience of the German Centre for Multiple Sclerosis in Childhood and Adolescence","volume":"255","author":"Stark","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.108010_bib0050","unstructured":"Swiss-Ped-IBrainD. (o. J.). Swiss-Ped-IBrainD. Accessed 11. January 2025, https:\/\/www.swiss-ped-ibraind.ch\/en\/about-the-registry\/."},{"issue":"2","key":"10.1016\/j.msard.2026.108010_bib0051","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.108010_bib0052","article-title":"Integrated addendum to ICH E6 (R1): guideline for good clinical practice, E6 (R2)","year":"2016","journal-title":"Curr. Step 4 version dated"},{"key":"10.1016\/j.msard.2026.108010_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.851426","article-title":"Analysis of the group of pediatric patients with relapsing-remitting multiple sclerosis: data from the Czech National Registry","volume":"13","author":"Vali\u0161","year":"2022","journal-title":"Front. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.108010_bib0054","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1474-4422(14)70093-6","article-title":"Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research","volume":"13","author":"Waldman","year":"2014","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.108010_bib0055","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/archneurol.2009.135","article-title":"Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults","volume":"66","author":"Waubant","year":"2009","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.108010_bib0056","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/brain\/112.6.1419","article-title":"The natural history of multiple sclerosis: a geographically based study: 2 predictive value of the early clinical course","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.108010_bib0057","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211039648","article-title":"Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)","volume":"14","author":"Wiendl","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.108010_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102260","article-title":"Epidemiology of pediatric multiple sclerosis: a systematic literature review and meta-analysis","volume":"44","author":"Yan","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2026.108010_bib0059","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrneurol.2009.158","article-title":"Pediatric multiple sclerosis","volume":"5","author":"Yeh","year":"2009","journal-title":"Nat. Rev. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482601045X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482601045X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:40:19Z","timestamp":1792802419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482601045X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":56,"alternative-id":["S221103482601045X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.108010","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment in pediatric-onset multiple sclerosis: Data from the Swiss pediatric inflammatory brain disease cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.108010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108010"}}